The Journal of Allergy and Clinical Immunology
Volume 119, Issue 5 , Pages 1174-1180 , May 2007

Probiotics in prevention of IgE-associated eczema: A double-blind, randomized, placebo-controlled trial

  • Thomas R. Abrahamsson, MD

      Affiliations

    • From the Department of Molecular and Clinical Medicine, Division of Pediatrics
    • Corresponding Author InformationReprint requests: Thomas R. Abrahamsson, MD, Division of Paediatrics, Linköping University Hospital, Linköping 581 85, Sweden.
    • These authors contributed equally to this work.
    • ,
  • Ted Jakobsson, MD

      Affiliations

    • From the Department of Molecular and Clinical Medicine, Division of Pediatrics
    • These authors contributed equally to this work.
    • ,
  • Malin Fagerås Böttcher, PhD

      Affiliations

    • From the Department of Molecular and Clinical Medicine, Division of Pediatrics
    • ,
  • Mats Fredrikson, PhD

      Affiliations

    • Department of Molecular and Clinical Medicine, Division of Occupational and Environmental Medicine, Linköping University
    • ,
  • Maria C. Jenmalm, PhD

      Affiliations

    • From the Department of Molecular and Clinical Medicine, Division of Pediatrics
    • ,
  • Bengt Björkstén, MD, PhD

      Affiliations

    • Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    • ,
  • Göran Oldaeus, MD, PhD

      Affiliations

    • Department of Pediatrics, County Hospital Ryhov, Jönköping

Received 28 August 2006 ,Revised 5 January 2007 ,Accepted 8 January 2007.

  • Image Result

    Participation rate and reason for discontinuation. Families were excluded if their baby was admitted to the neonatal ward during the first week of life or if they had a poor compliance. A total of 16

    Participation rate and reason for discontinuation. Families were excluded if their baby was admitted to the neonatal ward during the first week of life or if they had a poor compliance. A total of 16 of 19 families declining participation gave no reason, whereas 3 (2 in the L reuteri group) did so because of abdominal discomfort/colic.

  • Image Result
    Prevalence of any eczema (solid lines) and IgE-associated eczema (hatched lines) during the first 24 months of life in infants receiving daily oral supplementation of L reuteri (closed symbols) or pla

    Prevalence of any eczema (solid lines) and IgE-associated eczema (hatched lines) during the first 24 months of life in infants receiving daily oral supplementation of L reuteri (closed symbols) or placebo (open symbols) during the first 12 months of life. ∗P = .02 with χ2 test.

 Supported by grants from BioGaia AB, Stockholm, the Ekhaga Foundation, the Heart and Lung Foundation, the Research Council for the South-East Sweden (grant F2000-106), the Swedish Asthma and Allergy Association, the Swedish Research Council, and the University Hospital of Linköping.Disclosure of potential conflict of interest: B. Björkstén has consulting arrangements with BioGala Inc. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)00164-9

doi: 10.1016/j.jaci.2007.01.007

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 5 , Pages 1174-1180 , May 2007

Article Tools

* Image Usage & Resolution